1. Eribulin—A review of preclinical and clinical studies
Umang Swami, Imran Chaudhary, Mohammad H. Ghalib, Sanjay Goel 
Critical Reviews in Oncology / Hematology 
Volume 81, Issue 2, Pages (February 2012)
DOI: /j.critrevonc
Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1 Chemical structure of halichondrin B.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2 Chemical structure of eribulin mesylate.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

4. Fig. 3 Mechanism of action of eribulin (courtesy EISAI).
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

5. Fig. 4
Plasma Cmax versus dose following a 1-h infusion of eribulin on day 1. (B) Plasma area under the concentration–time curve (AUC0-8) versus dose following a 1-h infusion of eribulin on day 1. (C) Plasma concentration versus time profile for the 1.0mg/m2 treatment group (n=9).
From: Ref. [10].
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

6. Fig. 5
Eribulin related adverse events of interest or ≥10% incidence as seen in 394 patients with MBC [55,56].
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions